CSF3 and Miyoshi myopathy: Based on two pivotal phase III studies that will be described below, plerixafor was approved by the FDA in December 2008 for use in combination with G-CSF for mobilization of peripheral blood stem cells in patients with NHL and MM (Genzyme Corporation, 2008).